Free Trial
NASDAQ:IART

Integra LifeSciences (IART) Stock Price, News & Analysis

Integra LifeSciences logo
$15.08 +0.47 (+3.22%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$15.08 -0.01 (-0.03%)
As of 10/17/2025 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Integra LifeSciences Stock (NASDAQ:IART)

Advanced

Key Stats

Today's Range
$14.41
$15.14
50-Day Range
$12.75
$15.99
52-Week Range
$11.06
$27.13
Volume
1.13 million shs
Average Volume
989,432 shs
Market Capitalization
$1.17 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.17
Consensus Rating
Reduce

Company Overview

Integra LifeSciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
53rd Percentile Overall Score

IART MarketRank™: 

Integra LifeSciences scored higher than 53% of companies evaluated by MarketBeat, and ranked 512th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Integra LifeSciences has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on 2 buy ratings, 2 hold ratings, and 4 sell ratings.

  • Upside/Downside

    The consensus price target for Integra LifeSciences is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Integra LifeSciences has only been the subject of 3 research reports in the past 90 days.

  • Read more about Integra LifeSciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Integra LifeSciences are expected to grow by 2.04% in the coming year, from $2.45 to $2.50 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Integra LifeSciences is -2.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Integra LifeSciences is -2.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Integra LifeSciences has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Integra LifeSciences' valuation and earnings.
  • Percentage of Shares Shorted

    9.48% of the float of Integra LifeSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Integra LifeSciences has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Integra LifeSciences has recently decreased by 2.80%, indicating that investor sentiment is improving.
  • Dividend Yield

    Integra LifeSciences does not currently pay a dividend.

  • Dividend Growth

    Integra LifeSciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.48% of the float of Integra LifeSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Integra LifeSciences has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Integra LifeSciences has recently decreased by 2.80%, indicating that investor sentiment is improving.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Integra LifeSciences this week, compared to 6 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Integra LifeSciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.54% of the stock of Integra LifeSciences is held by insiders.

  • Percentage Held by Institutions

    84.78% of the stock of Integra LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Integra LifeSciences' insider trading history.
Receive IART Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Integra LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IART Stock News Headlines

Buy alert: Move $1,000 before Tesla’s Optimus launch
Elon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's preparing for a "mind blowing" new launch that could see Tesla move away from electric cars... and into a new market.tc pixel
Citi Reaffirms Their Sell Rating on Integra Lifesciences (IART)
See More Headlines

IART Stock Analysis - Frequently Asked Questions

Integra LifeSciences' stock was trading at $22.68 at the beginning of the year. Since then, IART shares have decreased by 33.5% and is now trading at $15.08.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) posted its quarterly earnings results on Thursday, July, 31st. The life sciences company reported $0.45 earnings per share for the quarter, topping analysts' consensus estimates of $0.43 by $0.02. Integra LifeSciences's revenue for the quarter was down .6% compared to the same quarter last year.
Read the conference call transcript
.

Integra LifeSciences shares split on the morning of Tuesday, January 3rd 2017.The 2-1 split was announced on Thursday, December 22nd 2016. The newly issued shares were payable to shareholders after the closing bell on Wednesday, December 21st 2016. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

The following companies are subsidiaries of Integra LifeSciences: ACell Inc, Rebound Therapeutics, Arkis BioSciences, Codman Neuro, TGX Medical Systems, Derma Sciences, Tekmed Instruments S.p.A, and more.

Top institutional shareholders of Integra LifeSciences include Assenagon Asset Management S.A. (0.58%), Wedge Capital Management L L P NC (0.08%), Exchange Traded Concepts LLC (0.05%) and Yousif Capital Management LLC (0.03%). Insiders that own company stock include Stuart Essig, Michael J Mcbreen, Lisa Evoli, Witte Jan De and Jeffrey Mosebrook.
View institutional ownership trends
.

Shares of IART stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Integra LifeSciences investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM), Tesla (TSLA) and Home Depot (HD).

Company Calendar

Last Earnings
7/31/2025
Today
10/19/2025
Next Earnings (Estimated)
10/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:IART
CIK
917520
Employees
4,396
Year Founded
1989

Price Target and Rating

High Price Target
$25.00
Low Price Target
$12.00
Potential Upside/Downside
+7.2%
Consensus Rating
Reduce
Rating Score (0-4)
1.75
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($6.53)
Trailing P/E Ratio
N/A
Forward P/E Ratio
6.16
P/E Growth
N/A
Net Income
-$6.94 million
Net Margins
-30.87%
Pretax Margin
-34.46%
Return on Equity
12.15%
Return on Assets
4.32%

Debt

Debt-to-Equity Ratio
1.18
Current Ratio
1.23
Quick Ratio
0.73

Sales & Book Value

Annual Sales
$1.61 billion
Price / Sales
0.73
Cash Flow
$4.45 per share
Price / Cash Flow
3.39
Book Value
$20.03 per share
Price / Book
0.75

Miscellaneous

Outstanding Shares
77,910,000
Free Float
75,153,000
Market Cap
$1.17 billion
Optionable
Optionable
Beta
1.21

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:IART) was last updated on 10/20/2025 by MarketBeat.com Staff
From Our Partners